{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036095","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.305717+00:00","generated_at":"2026-05-29T19:01:06.753542+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharmaceuticals acquires U.S. rights to Amglidia (glyburide oral suspension) for neonatal diabetes","bullets":["No upfront payment; up to $2.35M in milestone payments plus 14% royalty on net sales.","Amglidia approved by EMA in 2018, has U.S. FDA Orphan Drug Designation.","Targets neonatal diabetes, a rare condition affecting ~300 U.S. patients with no FDA-approved oral treatment.","Eton plans FDA meeting in Q1 2025 and expects NDA submission in 2026.","Eton can terminate within 30 days of FDA meeting minutes without milestone liability."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036095","json":"https://secwatch.observer/filing/0001437749-24-036095.json","markdown":"https://secwatch.observer/filing/0001437749-24-036095.md","text":"https://secwatch.observer/filing/0001437749-24-036095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/0001437749-24-036095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/eton20241117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:01:06.753542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}